Research Information System
Journal of Cancer Research and Therapeutics, vol.19, no.7, pp.1887-1892, 2023 (SCI-Expanded, Scopus)
Background: The goal of this study was to assess the clinicopathologic characteristics and prognostic variables in men with breast cancer (BC). Methods: Clinical features, pathological characteristics, stage at diagnosis, and therapy data were noted. Survival analysis was performed using the log-rank technique and Cox regression model. Results: Eighty patients were included in the study. In 31% of the individuals, BRCA (BReast CAncer genes 1 and 2) mutations were identified. The estrogen receptor (ER) positivity ratio was 93.6%, whereas the progesterone receptor (PR) positivity ratio was 74.4%. In 16.9% of the cases, HER2 overexpression was found. The median survival time was 120.9 months (70.3-171.5), and the five-year overall survival (OS) ratio was 74.9%. In univariate analysis, BRCA mutation status had no effect on OS (P = 0.50). CA15-3 levels (P = 0.03) at diagnosis and history of smoking (P = 0.03) were significantly linked with OS. However, the multivariate analysis could not confirm these results. Conclusions: We found that BRCA mutation, body mass index, a history of smoking, and alcohol consumption did not affect the OS in this research.